NCT/Study#
NCT05726383 /
MISTLETOE
ISCADOR® P (MISTLETOE) IMMUNOTHERAPY TO IMPROVE EVENT FREE SURVIVAL IN OSTEOSARCOMA PATIENTS WITH PULMONARY METASTASES
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
